FDA Cleared TriSalus Liver Drug Delivery Device
The approval allows specialized facilities to use the new TriNav Advance system for liver-directed therapy.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Do you trust that new medical device innovations make healthcare companies better long-term investments?
TriSalus Life Sciences secured 510(k) clearance from the FDA for its TriNav Advance drug delivery device. The technology is designed to facilitate liver-directed therapy by accessing distal vessels.
Why it matters
The clearance completes the company's product portfolio for liver embolization, providing clinicians with a pressure-enabled tool for delivering treatments to small vessels. Operators in specialized oncology and interventional radiology will monitor the device's market roll-out.
Shares rose 26% to $6.21 following the FDA clearance, though the stock finished the year-to-date period down 29%. The device is set to undergo a limited market release in the coming weeks.
The players
TriSalus Life Sciences
A medical technology company that develops pressure-enabled drug delivery devices for the treatment of liver and pancreatic tumors.
FDA
The federal regulatory body responsible for evaluating the safety and efficacy of medical devices before they enter the U.S. market.
The details
The TriNav Advance device utilizes pressure-enabled technology to deliver drugs to targeted areas of the liver. By employing a specialized microcatheter, the system is engineered to navigate small, distal vessels that are often difficult to access. This design is intended to support the full spectrum of liver embolization procedures in clinical settings.
Timeline
September 22, 2026: The FDA issued 510(k) clearance for the TriNav Advance device.
Tuesday, September 22, 2026: The company's stock closed at $4.93.
Coming weeks: The firm will initiate a limited market release of the new device.
Market Landscape
This clearance follows the established FDA 510(k) pathway, which provides a defined regulatory route for medical technology manufacturers to bring devices to market. The addition of the TriNav Advance unit marks the completion of the company's current liver-directed portfolio.
Operators in interventional radiology should monitor the upcoming limited market release for clinical performance data. Suppliers and providers should track how the device's pressure-enabled capabilities compare to existing embolization tool costs.
The takeaway
The addition of the TriNav Advance device completes a core product suite for liver-directed therapy. Managers should monitor future clinical outcome reports from the limited release to assess the device's competitive impact on existing embolization protocols.
Further reading
For broader context on current clinical technologies and regulatory trends, visit the Healthcare section.
Live Poll
Do you trust that new medical device innovations make healthcare companies better long-term investments?
